Experienced in Legius Syndrome

Dr. Priya U. Kumthekar

Northwestern Medical Faculty Foundation
Chicago, IL
Experienced
in Legius Syndrome
Specialties:Hematology Oncology | Neurology | Hematology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Priya Kumthekar is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Dr. Kumthekar and is rated as an Experienced provider by MediFind in the treatment of Legius Syndrome. Her top areas of expertise are Astrocytoma, Glioblastoma, Brain Tumor, and Glioma. Dr. Kumthekar is currently accepting new patients.

Her clinical research consists of co-authoring 101 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Neurology
Hematology
Licenses
Psychiatry & Neurology in IL
Hospital Affiliations
Northwestern Memorial Hospital
Palos Community Hospital
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna

Locations

NORTHWESTERN MEDICAL FACULTY FOUNDATION
675 N St Clair, 250 Dept Of Nephrology, Chicago, IL 60611
312-695-0596

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Suspended
Publish Date: February 25, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: December 16, 2024
Intervention Type: Drug, Device, Radiation
Study Drugs: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine
Study Phase: Phase 1/Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Depatuxizumab
Study Phase: Phase 3
Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD 1/PD-L1 Inhibitor as Their Most Recent Therapy
Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD 1/PD-L1 Inhibitor as Their Most Recent Therapy
Enrollment Status: Completed
Publish Date: February 27, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 0 First-In-Human Study Using NU-0129: A Spherical Nucleic Acid (SNA) Gold Nanoparticle Targeting BCL2L12 in Recurrent Glioblastoma Multiforme or Gliosarcoma Patients
A Phase 0 First-In-Human Study Using NU-0129: A Spherical Nucleic Acid (SNA) Gold Nanoparticle Targeting BCL2L12 in Recurrent Glioblastoma Multiforme or Gliosarcoma Patients
Enrollment Status: Completed
Publish Date: August 26, 2022
Intervention Type: Other, Drug
Study Phase: Early Phase 1
A Phase II, Open Label, Clinical Trial Of Pre-Surgical and Adjuvant Treatment of Recurrent Malignant Glioma With Tremelimumab and Durvalumab (MEDI4736) Alone and in Combination to Determine Immunologic Changes From Treatment
A Phase II, Open Label, Clinical Trial Of Pre-Surgical and Adjuvant Treatment of Recurrent Malignant Glioma With Tremelimumab and Durvalumab (MEDI4736) Alone and in Combination to Determine Immunologic Changes From Treatment
Enrollment Status: Completed
Publish Date: April 18, 2022
Intervention Type: Biological, Procedure, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
Enrollment Status: Completed
Publish Date: September 22, 2021
Intervention Type: Drug, Biological
Study Drugs: Ad-RTS-hIL-12, Veledimex
Study Phase: Phase 1
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Biological
Study Drugs: DNX-2401 Adeno-Associated Oncolytic Virus Delta-24 Vaccine, Pembrolizumab
Study Phase: Phase 2
A Phase II Trial of Bevacizumab in Patients With Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy
A Phase II Trial of Bevacizumab in Patients With Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy
Enrollment Status: Completed
Publish Date: September 17, 2019
Intervention Type: Procedure, Biological
Study Phase: Phase 2
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 13 Less Clinical Trials

101 Total Publications

Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.
Journal: JAMA oncology
Published: October 31, 2024
Similar Doctors
Expertise in
10
conditions
Dr. James Tonsgard
Pediatrics | Neurology
Expertise in
10
conditions
Dr. James Tonsgard
Pediatrics | Neurology

University Of Chicago

14290 S La Grange Rd, 
Orland Park, IL 
 (22.1 mi)
844-755-8267
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Tonsgard is a Pediatrics specialist and a Neurologist in Orland Park, Illinois. Dr. Tonsgard and is rated as an Elite provider by MediFind in the treatment of Legius Syndrome. His top areas of expertise are Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Neurofibromatosis Type 2 (NF2), and RASopathies.

Expertise in
33
conditions
Dr. Karan Dixit
Hematology Oncology | Neurology | Hematology
Expertise in
33
conditions
Dr. Karan Dixit
Hematology Oncology | Neurology | Hematology

Northwestern Medical Faculty Foundation

680 N Lake Shore Dr, Suite 810, 
Chicago, IL 
 (0.2 mi)
312-926-6146
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Karan Dixit is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Dr. Dixit and is rated as a Distinguished provider by MediFind in the treatment of Legius Syndrome. His top areas of expertise are Astrocytoma, Glioma, Brain Tumor, Glioblastoma, and Gastrostomy.

Expertise in
18
conditions
Dr. Stefania Maraka
Neurology
Expertise in
18
conditions
Dr. Stefania Maraka
Neurology

The Board Of Trustees Of The University Of Illinois

912 S Wood St, Uic Neurology, 
Chicago, IL 
 (3.5 mi)
312-996-6496
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stefania Maraka is a Neurologist in Chicago, Illinois. Dr. Maraka and is rated as a Distinguished provider by MediFind in the treatment of Legius Syndrome. Her top areas of expertise are Neurofibromatosis, Glioblastoma, Neurofibromatosis Type 1 (NF1), and Brain Tumor.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile